Page last updated: 2024-10-24

carmustine and Bone Loss, Osteoclastic

carmustine has been researched along with Bone Loss, Osteoclastic in 1 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Research Excerpts

ExcerptRelevanceReference
"Bone resorption was assessed by urinary free pyridinoline (fPyr) and deoxypyridinoline (fDPyr), expressed as a ratio of the urinary creatinine concentration."1.31Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. ( Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE, 2000)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clark, RE1
Flory, AJ1
Ion, EM1
Woodcock, BE1
Durham, BH1
Fraser, WD1

Other Studies

1 other study available for carmustine and Bone Loss, Osteoclastic

ArticleYear
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
    Blood, 2000, Oct-15, Volume: 96, Issue:8

    Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom

2000